Effect of lurasidone on neurocognitive performance in patients with schizophrenia: A short-term placebo- and active-controlled study followed by a 6-month double-blind extension

European Neuropsychopharmacology

Volumn 23, Issue 11, 2013, Pages 1373-1382

  Harvey, Philip D ^a   Siu, Cynthia O ^b   Hsu, Jay ^c   Cucchiaro, Josephine ^c   Maruff, Paul ^d   Loebel, Antony ^c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Data Power DP Inc   (United States)

^c DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^d Scientific Division   (Australia)

Author keywords

Functional capacity; Lurasidone; Neurocognitive performance; Schizophrenia

Indexed keywords

LURASIDONE; PLACEBO; QUETIAPINE;

ADULT; ARTICLE; COGNITION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EVENING DOSAGE; FEMALE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SCHIZOPHRENIA COGNITION RATING SCALE; SCORING SYSTEM; UNIVERSITY OF CALIFORNIA SAN DIEGO PERFORMANCE BASED SKILLS ASSESSMENT BRIEF;

FUNCTIONAL CAPACITY; LURASIDONE; NEUROCOGNITIVE PERFORMANCE; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; COGNITION; DELAYED-ACTION PREPARATIONS; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOINDOLES; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; THIAZOLES; TIME FACTORS;

EID: 84886799860     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.08.003     Document Type: Article

References (30)

1. Allison D.B., Loebel A.D., Lombardo I., et al. Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: effect modification or regression to the mean?. Psychiatry Res. 2009, 170:172-176.
2. Bowie C.R., Reichenberg A., Patterson T.L., et al. Determinants of real world functional performance in schizophrenia: correlations with cognition, functional capacity, and symptoms. Am. J. Psychiatry 2006, 163:418-425.
3. Buchanan R.W., Davis M., Goff D., et al. A summary of the FDA-NIMHMATRICS Workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr. Bull. 2005, 31:5-19.
4. Buchanan R.W., Kreyenbuhl J., Kelly D.L., et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr. Bull. 2010, 36:71-93.
5. Davidson M., Galderisi S., Weiser M., et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am. J. Psychiatry 2009, 166:675-682.
6. Davidson M., Keefe R.S. Cognitive impairment as a target for pharmacological treatment in schizophrenia. Schizophr. Res. 1995, 17:123-139.
7. Enomoto T., Ishibashi T., Tokuda K., et al. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav. Brain Res. 2008, 186:197-207.
8. Fitzmaurice G.M., Laird N.M., Ware J.H. Applied Longitudinal Analysis 2004, John Wiley & Sons, Inc., New Jersey.
9. Goldberg T.E., Koppel J., Keehlisen L., et al. Performance-based measures of everyday function in mild cognitive impairment. Am. J. Psychiatry 2010, 167:845-853.
10. Green M.G., Schooler N.R., Kern R.S., et al. Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. Am. J. Psychiatry 2011, 168:400-407.
11. Harvey P.D., Bellack A.S., Velligan D. Performance-based measures of functional skills: usefulness in clinical treatment studies. Schizophr. Bull. 2007, 33:1138-1148.
12. Harvey P.D., Keefe R.S.E. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry 2001, 158:176-184.
13. Harvey P.D., Ogasa M., Cucchiaro J., et al. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr. Res. 2011, 127:188-194.
14. Harvey P.D., Raykov T., Twamley E., et al. Validating the measurement of real-world functional outcomes: phase I results of the VALERO study. Am. J. Psychiatry 2011, 168:1195-1201.
15. Harvey P.D., Siu C.O., Romano S. Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology 2004, 172:324-332.
16. Horisawa T., Ishibashi T., Nishikawa H., et al. The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone. Behav. Brain Res. 2011, 220:83-90.
17. Ishibashi T., Horisawa T., Tokuda K., et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-HT7 and 5-HT1A receptor activity. J. Pharmacol. Exp. Ther. 2010, 334:171-181.
18. Ishibashi T., Tokuda K., Ishibashi T., et al. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur. J. Pharmacol. 2007, 572:160-170.
19. Javitt D.C., Buchanan R.W., Keefe R.S.E., et al. Effect of the neuroprotective peptide davinetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr. Res. 2012, 136:25-31.
20. Keefe R.S.E., Bilder R.M., Davis S.M., et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch. Gen. Psychiatry 2007, 64:633-647.
21. Keefe R.S.E., Buchanan R.W., Marder S.R. Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?. Schizophr. Bull. 2013, 39:417-435.
22. Keefe R.S.E., Fox K.H., Harvey P.D., et al. Characteristics of the MATRICS consensus cognitive battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr. Res. 2011, 125:161-168.
23. Keefe R.S.E., Silva S.G., Perkins D.O., et al. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr. Bull. 1999, 25:201-222.
24. Leifker F.R., Patterson T.L., Heaton R.K., et al. Validating measures of real-world outcome: the results of the VALERO expert survey and RAND panel. Schizophr. Bull. 2011, 37:334-343.
25. Loebel A., Cucchiaro J., Sarma K., et al. Efficacy and safety of lurasidone 80mg/day and 160mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr. Res. 2013, 145:101-109.
26. Loebel A., Cucchiaro J., Xu J., et al. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, continuation study. Schizophr. Res. 2013, 147:95-102.
27. Mausbach B.T., Harvey P.D., Goldman S.R., et al. Development of a brief scale of everyday functioning in persons with serious mental illness. Schizophr. Bull. 2007, 33:1364-1372.
28. Pietrzak R.H., Olver J., Norman T., et al. A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) battery in assessing cognitive impairment in chronic schizophrenia. J. Clin. Exp. Neuropsychol. 2009, 31:848-859.
29. Stahl S.M., Malla A., Newcomer J.W., et al. A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial. J. Clin. Psychopharmacol. 2010, 12:319-326.
30. Woodward N.D., Purdon S.E., Meltzer H.Y., et al. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 2005, 8:457-472.